142 related articles for article (PubMed ID: 23792047)
1. NMDA-receptor coagonists in serum, plasma, and cerebrospinal fluid of schizophrenia patients: a meta-analysis of case-control studies.
Brouwer A; Luykx JJ; van Boxmeer L; Bakker SC; Kahn RS
Neurosci Biobehav Rev; 2013 Sep; 37(8):1587-96. PubMed ID: 23792047
[TBL] [Abstract][Full Text] [Related]
2. Genome-wide association study of NMDA receptor coagonists in human cerebrospinal fluid and plasma.
Luykx JJ; Bakker SC; Visser WF; Verhoeven-Duif N; Buizer-Voskamp JE; den Heijer JM; Boks MP; Sul JH; Eskin E; Ori AP; Cantor RM; Vorstman J; Strengman E; DeYoung J; Kappen TH; Pariama E; van Dongen EP; Borgdorff P; Bruins P; de Koning TJ; Kahn RS; Ophoff RA
Mol Psychiatry; 2015 Dec; 20(12):1557-64. PubMed ID: 25666758
[TBL] [Abstract][Full Text] [Related]
3. Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia.
Hashimoto K; Fukushima T; Shimizu E; Komatsu N; Watanabe H; Shinoda N; Nakazato M; Kumakiri C; Okada S; Hasegawa H; Imai K; Iyo M
Arch Gen Psychiatry; 2003 Jun; 60(6):572-6. PubMed ID: 12796220
[TBL] [Abstract][Full Text] [Related]
4. Reduced D-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients.
Hashimoto K; Engberg G; Shimizu E; Nordin C; Lindström LH; Iyo M
Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jun; 29(5):767-9. PubMed ID: 15939521
[TBL] [Abstract][Full Text] [Related]
5. Significance of NMDA receptor-related glutamatergic amino acid levels in peripheral blood of patients with schizophrenia.
Ohnuma T; Arai H
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jan; 35(1):29-39. PubMed ID: 20828596
[TBL] [Abstract][Full Text] [Related]
6. Changes in plasma D-serine, L-serine, and glycine levels in treatment-resistant schizophrenia before and after clozapine treatment.
Yamamori H; Hashimoto R; Fujita Y; Numata S; Yasuda Y; Fujimoto M; Ohi K; Umeda-Yano S; Ito A; Ohmori T; Hashimoto K; Takeda M
Neurosci Lett; 2014 Oct; 582():93-8. PubMed ID: 25218715
[TBL] [Abstract][Full Text] [Related]
7. Changes in plasma glycine, L-serine, and D-serine levels in patients with schizophrenia as their clinical symptoms improve: results from the Juntendo University Schizophrenia Projects (JUSP).
Ohnuma T; Sakai Y; Maeshima H; Hatano T; Hanzawa R; Abe S; Kida S; Shibata N; Suzuki T; Arai H
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1905-12. PubMed ID: 18835577
[TBL] [Abstract][Full Text] [Related]
8. Decreased levels of D-aspartate and NMDA in the prefrontal cortex and striatum of patients with schizophrenia.
Errico F; Napolitano F; Squillace M; Vitucci D; Blasi G; de Bartolomeis A; Bertolino A; D'Aniello A; Usiello A
J Psychiatr Res; 2013 Oct; 47(10):1432-7. PubMed ID: 23835041
[TBL] [Abstract][Full Text] [Related]
9. Increased prevalence of diverse N-methyl-D-aspartate glutamate receptor antibodies in patients with an initial diagnosis of schizophrenia: specific relevance of IgG NR1a antibodies for distinction from N-methyl-D-aspartate glutamate receptor encephalitis.
Steiner J; Walter M; Glanz W; Sarnyai Z; Bernstein HG; Vielhaber S; Kästner A; Skalej M; Jordan W; Schiltz K; Klingbeil C; Wandinger KP; Bogerts B; Stoecker W
JAMA Psychiatry; 2013 Mar; 70(3):271-8. PubMed ID: 23344076
[TBL] [Abstract][Full Text] [Related]
10. The involvement of the NMDA receptor D-serine/glycine site in the pathophysiology and treatment of schizophrenia.
Labrie V; Roder JC
Neurosci Biobehav Rev; 2010 Mar; 34(3):351-72. PubMed ID: 19695284
[TBL] [Abstract][Full Text] [Related]
11. The behavioral and neurochemical effects of a novel D-amino acid oxidase inhibitor compound 8 [4H-thieno [3,2-b]pyrrole-5-carboxylic acid] and D-serine.
Smith SM; Uslaner JM; Yao L; Mullins CM; Surles NO; Huszar SL; McNaughton CH; Pascarella DM; Kandebo M; Hinchliffe RM; Sparey T; Brandon NJ; Jones B; Venkatraman S; Young MB; Sachs N; Jacobson MA; Hutson PH
J Pharmacol Exp Ther; 2009 Mar; 328(3):921-30. PubMed ID: 19088300
[TBL] [Abstract][Full Text] [Related]
12. Allosteric modulation of NMDA receptor via elevation of brain glycine and D-serine: the therapeutic potentials for schizophrenia.
Yang CR; Svensson KA
Pharmacol Ther; 2008 Dec; 120(3):317-32. PubMed ID: 18805436
[TBL] [Abstract][Full Text] [Related]
13. Relation of plasma glycine, serine, and homocysteine levels to schizophrenia symptoms and medication type.
Neeman G; Blanaru M; Bloch B; Kremer I; Ermilov M; Javitt DC; Heresco-Levy U
Am J Psychiatry; 2005 Sep; 162(9):1738-40. PubMed ID: 16135636
[TBL] [Abstract][Full Text] [Related]
14. [Development of a novel pharmacotherapy targeted at the N-methyl-D-aspartate receptor-D-serine system for schizophrenia].
Nishikawa T
Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Nov; 30(5-6):201-6. PubMed ID: 21226316
[TBL] [Abstract][Full Text] [Related]
15. D-Aspartate: An endogenous NMDA receptor agonist enriched in the developing brain with potential involvement in schizophrenia.
Errico F; Mothet JP; Usiello A
J Pharm Biomed Anal; 2015 Dec; 116():7-17. PubMed ID: 25868730
[TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal fluid D-serine and glycine concentrations are unaltered and unaffected by olanzapine therapy in male schizophrenic patients.
Fuchs SA; De Barse MM; Scheepers FE; Cahn W; Dorland L; de Sain-van der Velden MG; Klomp LW; Berger R; Kahn RS; de Koning TJ
Eur Neuropsychopharmacol; 2008 May; 18(5):333-8. PubMed ID: 18261886
[TBL] [Abstract][Full Text] [Related]
17. D-amino acid aberrations in cerebrospinal fluid and plasma of smokers.
Luykx JJ; Bakker SC; van Boxmeer L; Vinkers CH; Smeenk HE; Visser WF; Verhoeven-Duif NM; Strengman E; Buizer-Voskamp JE; de Groene L; van Dongen EP; Borgdorff P; Bruins P; de Koning TJ; Kahn RS; Ophoff RA
Neuropsychopharmacology; 2013 Sep; 38(10):2019-26. PubMed ID: 23615666
[TBL] [Abstract][Full Text] [Related]
18. Analysis of correlation between serum D-serine levels and functional promoter polymorphisms of GRIN2A and GRIN2B genes.
Iwayama Y; Hashimoto K; Nakajima M; Toyota T; Yamada K; Shimizu E; Itokawa M; Hoshika A; Iyo M; Yoshikawa T
Neurosci Lett; 2006 Feb; 394(2):101-4. PubMed ID: 16266783
[TBL] [Abstract][Full Text] [Related]
19. Plasma glycine and serine levels in schizophrenia compared to normal controls and major depression: relation to negative symptoms.
Sumiyoshi T; Anil AE; Jin D; Jayathilake K; Lee M; Meltzer HY
Int J Neuropsychopharmacol; 2004 Mar; 7(1):1-8. PubMed ID: 14720317
[TBL] [Abstract][Full Text] [Related]
20. Structural requirements for activation of the glycine coagonist site of N-methyl-D-aspartate receptors expressed in Xenopus oocytes.
McBain CJ; Kleckner NW; Wyrick S; Dingledine R
Mol Pharmacol; 1989 Oct; 36(4):556-65. PubMed ID: 2554111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
